Cargando…
JNK suppression of chemotherapeutic agents-induced ROS confers chemoresistance on pancreatic cancer stem cells
Chemoresistance associated with cancer stem cells (CSCs), which is now being held responsible for the pervasive therapy resistance of pancreatic cancer, poses a major challenge to the successful management of this devastating malignancy. However, the molecular mechanism underlying the marked chemore...
Autores principales: | Suzuki, Shuhei, Okada, Masashi, Shibuya, Keita, Seino, Manabu, Sato, Atsushi, Takeda, Hiroyuki, Seino, Shizuka, Yoshioka, Takashi, Kitanaka, Chifumi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4381607/ https://www.ncbi.nlm.nih.gov/pubmed/25473894 |
Ejemplares similares
-
Targeting the K-Ras - JNK axis eliminates cancer stem-like cells and prevents pancreatic tumor formation
por: Okada, Masashi, et al.
Publicado: (2014) -
Targeting the facilitative glucose transporter GLUT1 inhibits the self-renewal and tumor-initiating capacity of cancer stem cells
por: Shibuya, Keita, et al.
Publicado: (2014) -
The novel JNK inhibitor AS602801 inhibits cancer stem cells in vitro and in vivo
por: Okada, Masashi, et al.
Publicado: (2016) -
Therapeutic targeting of pancreatic cancer stem cells by dexamethasone modulation of the MKP-1–JNK axis
por: Suzuki, Shuhei, et al.
Publicado: (2021) -
Targeting JNK for therapeutic depletion of stem-like glioblastoma cells
por: Matsuda, Ken-ichiro, et al.
Publicado: (2012)